A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus

Trial Profile

A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Anifrolumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 15 Apr 2016 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.
    • 15 Apr 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2018.
    • 20 May 2015 Planned End Date changed from 1 Sep 2017 to 1 Apr 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top